Introduction
============

Arginine vasopressin (AVP) is a peptide hormone that is released in response to osmotic and haemodynamic changes in order to maintain fluid volume and vascular tone. As a \'stress hormone\', AVP is significantly increased in acute haemodynamic instability \[[@B1]\]. Copeptin is a stable fragment of pre-pro-vasopressin that is released in equimolar quantities as AVP, and thus reflects levels of released AVP. Unlike AVP, copeptin is highly stable *ex vivo*and is thus used for analysis. We aimed to study whether copeptin is elevated in any form of acute haemodynamic instability (that is, shock state) and whether copeptin is a predictor of outcome in critically ill patients.

Methods
=======

A total of 352 consecutive patients (65% male, 64 ± 15 years, SAPS 2 52 ± 23) admitted to the ICU of the Department of Cardiology/Medical University of Vienna were included. Blood samples were obtained on admission in all patients. Copeptin was determined using a recently developed immunoassay in the chemiluminescence/coated tube format \[[@B2]\].

Results
=======

Two hundred and seventy-seven patients survived to ICU discharge and 75 patients died. Copeptin plasma levels were significantly higher in ICU nonsurvivors than in ICU survivors (194 ± 205 pmol/l vs 101 ± 100 pmol/l; *P*\< 0.0001). The area under the ROC curve for prediction of ICU survival was 0.678 for copeptin. Patients with diagnosis of shock (*n*= 132) had significantly higher copeptin plasma levels than patients without shock (174 ± 169 pmol/l vs 93 ± 100 pmol/l; *P*\< 0.0001). There was no statistically significant difference in copeptin plasma levels between patients with different shock forms. Using a Kaplan--Meier model for 28-day survival, patients with copeptin plasma levels above the mean had significantly lower survival rates compared with patients with copeptin plasma levels below the mean (*P*= 0.03).

Conclusion
==========

In critically ill patients, elevated plasma levels of copeptin are a strong and independent predictor of adverse outcome. Copeptin is significantly increased in shock patients, independent of the shock category.
